8-K Announcements
6Material company update
May 14, 2026·SEC
Material company update
Apr 3, 2026·SEC
Material company update
Mar 26, 2026·SEC
Arcadia Biosciences, Inc.(RKDA)Earnings, Financials & Key Ratios
RKDA•NASDAQ
$0.72
Price updated Jul 6, 2026
AboutArcadia Biosciences, Inc. produces and markets plant-based health and wellness products in the United States. It engages in developing crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients, health and wellness products, and their viability for industrial applications. The company was incorporated in 2002 and is headquartered in Davis, California.Show more
- Revenue$5M-3.7%
- EBITDA-$10M-181.8%
- Net Income-$2M+66.8%
- EPS (Diluted)-1.71+66.9%
- Gross Margin36.23%-12.2%
- EBITDA Margin-205.08%-192.7%
- Operating Margin-205.74%-184.5%
- Net Margin-48.15%+65.5%
- ROE-45.14%+39.3%
RKDA Price & Volume
Arcadia Biosciences, Inc. (RKDA) stock price & volume — 10-year historical chart
Loading chart...
Persistent Revenue Contraction Threatens Corporate Liquidity Survival
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Decelerating
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity exhaustion
Key Thesis Takeaways
- Arcadia Biosciences faces a critical existential threat as its transition to an intellectual property licensing model fails to generate sustainable revenue, evidenced by a 8.3% year-over-year decline in 2026Q1.
- The company's inability to achieve operational scale has resulted in a massive $285.6 million accumulated deficit, severely eroding shareholder equity.
- Investors should remain cautious as the firm's minimal cash reserves of $954,000 as of 2026Q1 suggest an imminent need for dilutive financing or a potential asset liquidation event.
Verdict Logic
the company's cash position of $954,000 against a $1.1 million quarterly cash burn rate indicates a critical liquidity risk that outweighs any potential latent value in its patent portfolio.
RKDA Growth Metrics
Arcadia Biosciences, Inc. (RKDA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-1.08%
5 Years-9.57%
3 Years-13.16%
TTM-9.53%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-362.45%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-361.49%
Return on Capital
10 Years-61.02%
5 Years-63.85%
3 Years-62.1%
Last Year-129.46%
Peers Comparison
Key metrics vs top competitors for Arcadia Biosciences, Inc. (RKDA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.72 | $1.11M | -0.42 | -3.71% | -48.15% | -45.14% | — | |
| $5.60 | $1.68B | -3.97 | 146.73% | -646.99% | -1768.51% | — | |
| $11.57 | $467.68M | -5.07 | 2.85% | -7.27% | -13.44% | — | |
| $1.05 | $7.87M | -1.01 | -19.48% | -23.07% | — | — | |
| $86.39 | $58B | 53.99 | 2.92% | 6.5% | 4.62% | — | |
| $11.38 | $1.42B | -0.64 | -18.34% | -72.93% | -82.27% | — |
Compare RKDA vs Peers
Arcadia Biosciences, Inc. (RKDA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
RKDA SEC Filings & Documents
Arcadia Biosciences, Inc. (RKDA) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when RKDA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
RKDA Frequently Asked Questions
Arcadia Biosciences, Inc. (RKDA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Arcadia Biosciences, Inc.'s revenue?
Arcadia Biosciences, Inc. (RKDA) reported $4.8M in revenue for fiscal year 2025. This represents a 32% decrease from $7.0M in 2012.
How fast is Arcadia Biosciences, Inc. growing?
Arcadia Biosciences, Inc. (RKDA) saw revenue decline by 3.7% over the past year.
Is RKDA profitable?
Arcadia Biosciences, Inc. (RKDA) reported a net loss of $9.3M for fiscal year 2025.
Dividend & Returns
What is RKDA's return on equity?
Arcadia Biosciences, Inc. (RKDA) has a return on equity (ROE) of -45.1%. Negative ROE indicates the company is unprofitable.
What is Arcadia Biosciences, Inc.'s free cash flow?
Arcadia Biosciences, Inc. (RKDA) had negative free cash flow of $4.3M in fiscal year 2025, likely due to heavy capital investments.